« Back
Home /
Pazopanib (Hydrochloride)

Pazopanib (Hydrochloride)

Item no.	HY-12009-25mg
Manufacturer	MedChem Express
CASRN	635702-64-6
Amount	25 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer
Type	Inhibitors
Specific against	other
Purity	99.99
Citations	[1]Harris PA, et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem. 2008, 51(15), 4632-4640.\|[2]Thakur A, et al. Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage. Microvasc Res. 2011 Nov;82(3):346-50. Cell Signal. 2025 Nov:135:112054. ACS Chem Biol. 2017 May 19;12(5):1245-1256. Acta Pharmacol Sin. 2021 Jan;42(1):108-114. Acta Pharmacol Sin. 2023 Jun;44(6):1135-1148. Bioengineering (Basel). 2025 Oct 19;12(10):1121. Biomaterials. 2022 Oct:289:121800. bioRxiv. 2024 Mar 12:2024.03.11.584490. bioRxiv. 2025 Jul 12:2025.07.08.663754. bioRxiv. 2025 Sep 21. Cell Metab. 2021 Oct 5;33(10):2021-2039.e8. Cell Physiol Biochem. 2016;38(3):926-38. Cell Rep Med. 2025 Apr 2:102053. Cell Rep Methods. 2023 Oct 23;3(10):100599. Cell Syst. 2018 Apr 25;6(4):424-443.e7. Exp Cell Res. 2020 Aug 1;393(1):112054. Harvard Medical School LINCS LIBRARY Hong Kong Polytechnic University. 2025. Hum Cell. 2024 Dec 3;38(1):25. J BUON. Jan-Feb 2020;25(1):464-471. J Cell Sci. 2015 Sep 1;128(17):3317-29. J Toxicol Sci. 2024;49(8):337-348. Patent. US20210299273A1. PLoS One. 2024 Nov 1;19(11):e0308647. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
Smiles	CC1=CC=C(C=C1S(N)(=O)=O)NC2=NC=CC(N(C3=CC4=NN(C(C)=C4C=C3)C)C)=N2.Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	GW786034 (Hydrochloride)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound1
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - HS Code	H302, H315, H319, H335
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Product Description	Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
Manufacturer - Research Area	Cancer
Solubility	DMSO : 10 mg/mL (ultrasonic)
Manufacturer - Pathway	Autophagy; Protein Tyrosine Kinase/RTK
Clinical information	Launched
Isoform	PDGFRβ; VEGFR1/Flt-1; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4
UNSPSC Code	12352005
Precautionary	H302, H315, H319, H335

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.